Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 2(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04267640Phase 2Unknown

Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

Role: lead

NCT00189540Phase 2Completed

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

Role: lead

NCT02016755Phase 2Completed

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

Role: lead

NCT02974179Completed

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

Role: lead

NCT02144610Phase 3Terminated

Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia

Role: lead

NCT00060892Phase 2Completed

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

Role: lead

All 6 trials loaded